Inspire Medical’s EURO-STIM Registry: A Long-Term Look at Sleep Apnea Treatment

Inspire Medical ((INSP)) announced an update on their ongoing clinical study.

Study Overview: The EURO-STIM Registry, officially titled ‘Longitudinal Outcomes and Adherence of the Inspire System, EURO-STIM Registry,’ aims to measure the long-term outcomes and adherence of the Inspire System in patients with Obstructive Sleep Apnea (OSA). This study is significant as it seeks to capture the life cycle of the patient’s use of the Inspire System through routine clinical care visits, providing valuable insights into its effectiveness and patient adherence over time.

Intervention/Treatment: The intervention being tested is the Inspire UAS System, a permanent, implantable device designed to treat Obstructive Sleep Apnea. It consists of an implantable pulse generator (IPG), a stimulation lead, and a sensing lead, along with a remote control for patients to activate the therapy.

Study Design: This is an observational cohort study with a prospective time perspective. The study does not involve any specific allocation or masking, focusing instead on observing the natural use and outcomes of the Inspire System over a target duration of 10 years.

Study Timeline: The study began on April 7, 2025, with the latest update submitted on September 2, 2025. These dates are crucial as they indicate the study’s current recruiting status and ongoing data collection, which is vital for tracking the long-term effectiveness of the Inspire System.

Market Implications: This study update could positively influence Inspire Medical’s stock performance by reinforcing investor confidence in the long-term viability and effectiveness of the Inspire System. As the company continues to gather data, it positions itself strongly against competitors in the sleep apnea treatment market, potentially enhancing its market share and investor sentiment.

The EURO-STIM Registry is currently ongoing, with further details available on the ClinicalTrials portal.